NCT05202912已完成1 期
A Randomized, Open-label, Single-dose, Crossover Phase 1 Clinical Trial to Evaluate the Effects of Food or Ethnicity on the Pharmacokinetics and Safety/Tolerability of IDX-1197 After Single Oral Administration in Healthy Male Korean, Chinese, and Caucasian Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 37
- 试验地点
- 1
- 主要终点
- Cmax of IDX-1197
研究概览
简要总结
Study to Evaluate the Effects of Food or Ethnicity on the Pharmacokinetics and Safety/Tolerability of IDX-1197 After Single Oral Administration in Healthy Male Korean, Chinese, and Caucasian Volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male Korean, Chinese, or Caucasian adults at the age of ≥19 to ≤50 years old at the time of written informed consent:
- •Body weight ≥55.0 kg AND body mass index (BMS) ≥18.0 kg/m2 to <30.0 kg/m2 at screening: BMI(kg/m2) = body weight (kg) / {height (m)}2
- •The subject must voluntarily decide to participate in the study after being informed of, and fully understanding, details of the study; written informed consent must be obtained prior to any of the screening procedures.
- •Eligible for this study as determined by the investigator based on physical examinations, clinical laboratory tests, and interviews.
排除标准
- •Evidence or history of clinically significant hepatic, renal, neurological, respiratory, endocrine, blood and tumor, cardiovascular, urinary, and psychiatric disorders.
- •Evidence or history of gastrointestinal disorders (gastrointestinal ulcer, gastritis, gastrodynia, gastroesophageal reflux disease, Crohn's disease, etc.) that might affect the safety and PK of IP and/or history of gastrointestinal surgery (except for simple appendectomy and hernia repair).
- •Hypersensitivity to drugs or history of any clinically significant hypersensitivity.
- •Any of the following screening test results:
- •Hemoglobin level < 12.0 g/dL
- •Creatinine clearance: <60 mL/min/1.73m2 as calculated by the equation of Modification of Diet in Renal Disease
- •QTc interval: > 450 ms
- •Positive serum tests (hepatitis B, hepatitis C, human immunodeficiency virus, syphilis)
- •Screening systolic blood pressure <90 mmHg or >150 mmHg and/or diastolic blood pressure <60 mmHg or >100 mmHg as measured in sitting position after ≥3 minutes of rest.
- •History of drug abuse or a positive urine screening test for drugs of abuse.
- •Prior or expected treatment with any prescription drugs or herbal medicine within 2 weeks and/or any over the counter drugs, health functional foods, or vitamins within 1 week prior to the planned first IP dosing (individuals who are determined to be eligible at the discretion of the investigator based on other criteria will be allowed to participate in the study).
- •Treatment with drug metabolizing enzyme inducers and/or suppressors such as barbitals within 1 month prior to the planned first IP dosing.
- •Having participated in another clinical trial or a bioequivalence study and administered any IP within 6 months prior to the planned first IP dosing in the present study.
- •Whole blood donation within 2 months and/or apheresis donation within 1 month and/or blood transfusion within 1 month prior to the planned first IP dosing.
- •Continuous, excessive caffeine intake or continuous alcohol intake or unable to refrain from caffeine/alcohol consumption during hospitalization.
- •Current smoker (individuals who stopped smoking 3 months prior may be included in the study) or unable to stop smoking from 3 months prior to the planned first IP dosing to the last hospital discharge.
- •Having had any foods containing grapefruits from 24 hours prior to hospital admission to discharge in each period/cohort and/or unable to refrain from having foods containing grapefruits during the same period of time.
- •Unable to refrain from having foods containing caffeine (coffee, tea [black tea, green tea, etc.], carbonated drink, coffee milk, nutrients and tonics, etc.) from 24 hours prior to hospital admission to discharge in each period/cohort.
- •Individual or his spouse/partner who is unable to use medically acceptable methods of contraception throughout the study plus for at least 3 months from the last IP dosing and who does not agree not to donate sperm during the same period of time.
- •Ineligible for study participation in the opinion of the investigator for other reasons including clinical laboratory test results.
研究组 & 干预措施
Cohort A(Food effect)
Other
干预措施: IDX-1197(After a meal) (Drug)
Cohort B(Single dose)
Other
干预措施: IDX-1197(fasting) (Drug)
结局指标
主要结局
Cmax of IDX-1197
时间窗: through study completion, an average of 1 year
PK parameters will be assessed using plasma IDX-1197 concentrations measured
AUClast of IDX-1197
时间窗: through study completion, an average of 1 year
PK parameters will be assessed using plasma IDX-1197 concentrations measured
次要结局
- t1/2 of IDX-1197(through study completion, an average of 1 year)
- Vd/F of IDX-1197(through study completion, an average of 1 year)
- AUCinf of IDX-1197(through study completion, an average of 1 year)
- CL/F of IDX-1197(through study completion, an average of 1 year)
- Tmax of IDX-1197(through study completion, an average of 1 year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy SubjectsHealthy VolunteerNCT04204629Hanmi Pharmaceutical Company Limited25
已完成
1 期
Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits StudyChagas' DiseaseNCT03334838Bayer36
已完成
1 期
A Study to Evaluate the Effect of Food on Levofloxacin Pharmacokinetics From an Oral Solution FormulationHealthyNCT00601432Johnson & Johnson Pharmaceutical Research & Development, L.L.C.24
已完成
1 期
Food Effect Study of Linerixibat Tablets in Healthy Adult ParticipantsPruritusNCT05435170GlaxoSmithKline23
已完成
1 期
A Study of JNJ-64417184, Administered as an Oral Solution, in Healthy ParticipantsHealthyNCT04258189Janssen Research & Development, LLC16